Elusys Therapeutics

NightHawk Biosciences Provides Q3 2023 Business Update

Retrieved on: 
Monday, November 20, 2023
Marketing, Depreciation, Ecosystem, Form 10-K, Annual report, Sale, Drug development, Software, Research, CDMO, Therapy, Clinical trial, Insurance, Elusys Therapeutics, Investment, Growth, Scorpius, Life, Pharmaceutical industry

DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of innovative therapies, today provided strategic, financial, and operational updates for the quarter ended September 30, 2023.

Key Points: 
  • DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of innovative therapies, today provided strategic, financial, and operational updates for the quarter ended September 30, 2023.
  • As a result, we are currently evaluating a variety of strategic options to maximize the potential of the business.
  • Selling, general and administrative expenses were $6.1 million and $4.8 million for the three months ended September 30, 2023 and 2022, respectively.
  • NightHawk Biosciences leverages its integrated ecosystem of subsidiaries to streamline the advancement of novel therapies, breaking through barriers that prolong traditional drug development.

NightHawk Biosciences Provides 2022 Year End Business Update

Retrieved on: 
Friday, March 31, 2023
Insurance, Obiltoxaximab, Marketing, Bank statement, Scorpion, CMC, Disclosure, Research, Nighthawk, Sale, Government, Acquisition, Investment, Immune system, Depreciation, NYSE, Cryptocurrency, Pharmaceutical industry, Elusys Therapeutics

For the year ended December 31, 2021, the Company recognized revenue of $2.1 million for qualified expenditures under the CPRIT grant.

Key Points: 
  • For the year ended December 31, 2021, the Company recognized revenue of $2.1 million for qualified expenditures under the CPRIT grant.
  • Selling, general and administrative (“SGA”) expenses for the years ended December 31, 2022 and 2021 were $21.1 million and $16.8 million, respectively.
  • Research and development expenses increased to $23.5 million from $16.5 million for the years ended December 31, 2022 and 2021, respectively.
  • As of December 31, 2022, the Company had approximately $44.3 million in cash, cash equivalents, and short-term investments.

NightHawk Biosciences Provides Third Quarter 2022 Business Update

Retrieved on: 
Monday, November 14, 2022
Marketing, Growth, Immune system, Acquisition, Nighthawk, Life, Government, CDMO, Scorpion, Maintenance, Research, Drug development, Annual report, NYSE, Sale, Form 10-K, Ecosystem, Investment, Safety, Pharmaceutical industry, Elusys Therapeutics

DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates for the third quarter ended September 30, 2022.

Key Points: 
  • DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates for the third quarter ended September 30, 2022.
  • Jeff Wolf, Chief Executive Officer of NightHawk, commented, We are continuing to progress our biodefense and biomanufacturing efforts within our Elusys and Scorpion subsidiaries.
  • Recognized $6.0 million of revenue for the quarter ended September 30, 2022, which included $5.98 million of product sales revenue, $0.06 million of contract revenue, and no CPRIT grant revenue.
  • NightHawk Biosciences is a fully-integrated biopharmaceutical company focused on the discovery and commercialization of innovative medical countermeasures to defend against emerging biothreats.

Nighthawk Biosciences’ Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility

Retrieved on: 
Friday, October 21, 2022
Time, Sale, SEC, Life, Efficiency, Growth, NYSE, Drug development, Nighthawk, Twitter, Annual report, Private Securities Litigation Reform Act, Form 10-K, Elusys Therapeutics, Immune system, Company, Marketing, Industry, Ecosystem, Safety, GLOBE, Maintenance, Terminology, FDA, Pharmaceutical industry, Fine chemical, Scorpion, CDMO

DURHAM, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that its Scorpion subsidiary plans to host the grand opening of its San Antonio facility today, October 21.

Key Points: 
  • DURHAM, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that its Scorpion subsidiary plans to host the grand opening of its San Antonio facility today, October 21.
  • David Halverson, President of Scorpion, commented, We are pleased with the recent FDA feedback regarding our design, operational strategy, and environmental controls relevant to clinical and commercial manufacturing at our San Antonio facility.
  • These two facilities, once fully operational, will provide Scorpion with substantial biomanufacturing capabilities to accommodate future worldwide demand for biologic manufacturing.
  • Scorpion provides a broad array of clinical-scale biomanufacturing, analytical and R&D services to pharmaceutical and biotech companies from its San Antonio, Texas facilities.

NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory

Retrieved on: 
Tuesday, August 23, 2022
Safety, NYSE, Nighthawk, HVAC, Form 10-K, Anthrax, Therapy, Life, Vaccine, Doctor of Philosophy, Time, Sale, Maintenance, Toxin (comics), SEC, HEPA, Infection, PAPR, Triangle Park (Quezon City), CDMO, GLOBE, Classification, Company, Immune system, Population, DOD, Twitter, Terminology, Marketing, Tularemia, Ecosystem, Annual report, Private Securities Litigation Reform Act, Growth, Drug development, Acquisition, Monkeypox, Elusys Therapeutics, Research

The buildout of this facility follows our acquisition of biodefense company Elusys Therapeutics and represents the next stage in our efforts to develop medical countermeasures to protect the population against emerging biothreats.

Key Points: 
  • The buildout of this facility follows our acquisition of biodefense company Elusys Therapeutics and represents the next stage in our efforts to develop medical countermeasures to protect the population against emerging biothreats.
  • Matthew M. Seavey, PhD, Vice President of Research of NightHawk commented, This new BSL-2 facility is being designed to accommodate research on high-priority infectious agents.
  • NightHawk Biosciences is a fully-integrated biopharmaceutical company focused on the development of new drugs from discovery through commercialization.
  • For more information on the Company and is subsidiaries, please visit: www.nighthawkbio.com , and also follow us on Twitter .

NightHawk Biosciences Provides Second Quarter 2022 Business Update

Retrieved on: 
Wednesday, August 10, 2022
Nighthawk, NYSE, GLOBE, CDMO, Ecosystem, Private Securities Litigation Reform Act, Growth, SEC, Sale, Research, Life, Marketing, Elusys Therapeutics, Â, Company, Twitter, Form 10-K, Drug development, Safety, Maintenance, Time, Annual report, Immune system, Terminology, Fine chemical, Pharmaceutical industry

DURHAM, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates for the second quarter ended June 30, 2022.

Key Points: 
  • DURHAM, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates for the second quarter ended June 30, 2022.
  • Jeff Wolf, Chief Executive Officer of NightHawk, commented, We continue to advance our evolution towards becoming a fully-integrated biopharmaceutical company via our subsidiary ecosystem.
  • Recognized $0.05 million of contract revenue for the quarter ended June 30, 2022 compared to $0.5 million of grant and contract revenue for the quarter ended June 30, 2021.
  • NightHawk Biosciences is a fully-integrated biopharmaceutical company focused on the development of new drugs from discovery through commercialization.

NightHawk Biosciences Appoints Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services

Retrieved on: 
Monday, June 13, 2022
Process engineering, Life, Time, Company, Marketing, DCAT, Customer, Drug, Form 10-K, Institute of technology, Annual report, CEO, Multi-divisional form, Organization, Ecosystem, Maintenance, Sale, Growth, Lonza Group, GLOBE, Private Securities Litigation Reform Act, Technical University of Munich, NYSE, Director, Immune system, Nighthawk, Ghulam Ishaq Khan Institute of Engineering Sciences and Technology, Twitter, SEC, Association, Board, Elusys Therapeutics, Drug development, Interim, Safety, Terminology, Pharmaceutical industry, Fine chemical, Chemical substance, Engineering, Scorpion, CDMO

DURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the appointment of Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services.

Key Points: 
  • DURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the appointment of Stephan Kutzer, Ph.D. as Interim Chief Executive Officer of Scorpion Biological Services.
  • He previously served as President and Chief Executive Officer of Alcami Corporation, a leading provider of development, analytical testing and manufacturing services to the pharmaceutical and biotech industries.
  • Scorpion Biological Services is a contract research, and contract development and manufacturing organization (CDMO) focused on cell- and gene-based therapies and large molecule biologics.
  • NightHawk Biosciences is a fully integrated biopharmaceutical company focused on the development of new drugs from discovery through commercialization.

NightHawk Biosciences Provides First Quarter 2022 Business Update

Retrieved on: 
Monday, May 16, 2022
Contract, Company, Private Securities Litigation Reform Act, Research, Annual report, Â, Investment, Form 10-K, Government, Therapy, Marketing, Efficiency, Heat Biologics, Infection, Life, Time, Terminology, Safety, Sale, Ecosystem, Drug development, Maintenance, Immune system, Twitter, Nighthawk, Acquisition, SEC, Growth, NYSE, GLOBE, Pharmaceutical industry, Fine chemical, Cryptocurrency, CDMO, Elusys Therapeutics

DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates for the first quarter ended March 31, 2022.

Key Points: 
  • DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates for the first quarter ended March 31, 2022.
  • Jeff Wolf, Chief Executive Officer of NightHawk, commented, We are extremely proud of the progress we have made this quarter to transition NightHawk into a fully-integrated biopharmaceutical company.
  • Recognized $0.2 million of grant revenue for qualified expenditures under the CPRIT grant for the quarter ended March 31, 2022 compared to $0.5 million for the quarter ended March 31, 2021.
  • NightHawk Biosciences is a fully integrated biopharmaceutical company focused on the development of new drugs from discovery through commercialization.

Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today

Retrieved on: 
Tuesday, May 3, 2022
Drug development, Ecosystem, Heat Biologics, Private Securities Litigation Reform Act, Immune system, Twitter, Maintenance, GLOBE, Company, NYSE, Annual report, Safety, Time, Drug discovery, Industry, Form 10-K, Elusys Therapeutics, Marketing, Sale, SEC, Life, Terminology, CEO, Growth, Therapy, Fine chemical, Pharmaceutical industry

In connection with the name change, the Companys ticker will change to NHWK, effective today, May 3, 2022.

Key Points: 
  • In connection with the name change, the Companys ticker will change to NHWK, effective today, May 3, 2022.
  • Jeff Wolf, CEO of Nighthawk, commented, The NightHawk brand better reflects our evolution towards a fully integrated ecosystem, designed to efficiently move drugs from discovery through commercialization.
  • As a result, we have organized the Company around five key subsidiaries: Skunkworx Bio , Heat Biologics , Pelican Therapeutics , Elusys Therapeutics and Scorpion Biological Services .
  • NightHawk Biosciences is a fully integrated biopharmaceutical company focused on the development of new drugs from discovery through commercialization.

Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company’s Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities

Retrieved on: 
Tuesday, April 19, 2022
Drug development, Annual report, Thought, Marketing, Adult, Nighthawk, Twitter, Research, Bacillus anthracis, Life, Private Securities Litigation Reform Act, Hypersensitivity, Drug discovery, GLOBE, Anaphylaxis, Terminology, Patient, Sale, Infection, American Association for Cancer Research, Form 10-K, Kansas State University, Scorpion, Efficiency, Growth, Heat Biologics, Company, Immune system, Anthrax, Ecosystem, Discovery, Nasdaq, Maintenance, SEC, Joint Chiefs of Staff, NYSE, Investment, Safety, American Association, Acquisition, Chief of staff, Risk, AACR, Obiltoxaximab, Therapy, Time, Pharmaceutical industry, Pelican, Elusys Therapeutics, Heat

In connection with the name change, the Companys ticker will change to NHWK, effective May 3, 2022.

Key Points: 
  • In connection with the name change, the Companys ticker will change to NHWK, effective May 3, 2022.
  • The Company believes this fully-integrated ecosystem enables a more rapid delivery of medical innovations with increased quality and efficiency.
  • Scorpion is expected to host the grand opening of its San Antonio facility following completion of construction in Q3, 2022.
  • About Heat Biologics / NightHawk Biosciences, Inc.
    Heat Biologics (to become NightHawk Biosciences) is a fully-integrated biopharmaceutical company focused on the development of new drugs from discovery through manufacturing.